IQVIA (NYSE:IQV) Stock Sale Disclosed by Rep. Kevin Hern

Representative Kevin Hern (Republican-Oklahoma) recently sold shares of IQVIA Holdings Inc. (NYSE:IQV). In a filing disclosed on September 25th, the Representative disclosed that they had sold between $1,001 and $15,000 in IQVIA stock on September 8th. The trade occurred in the Representative’s “GABRIELLE ASHTYN HERN TRUST” account.

Representative Kevin Hern also recently made the following trade(s):

• Sold $15,001 – $50,000 in shares of CenterPoint Energy (NYSE:CNP) on 9/15/2026.
• Sold $1,001 – $15,000 in shares of TJX Companies (NYSE:TJX) on 9/15/2026.
• Sold $15,001 – $50,000 in shares of STERIS (NYSE:STE) on 9/15/2026.
• Sold $1,001 – $15,000 in shares of Seagate Technology (NASDAQ:STX) on 9/15/2026.
• Sold $15,001 – $50,000 in shares of NextEra Energy (NYSE:NEE) on 9/14/2026.
• Sold $1,001 – $15,000 in shares of Marsh & McLennan Companies (NYSE:MRSH) on 9/14/2026.
• Sold $15,001 – $50,000 in shares of IQVIA (NYSE:IQV) on 9/14/2026.
• Sold $15,001 – $50,000 in shares of Home Depot (NYSE:HD) on 9/14/2026.
• Sold $1,001 – $15,000 in shares of Home Depot (NYSE:HD) on 9/14/2026.
• Sold $15,001 – $50,000 in shares of Emerson Electric (NYSE:EMR) on 9/14/2026.

IQVIA Stock Up 0.2%

NYSE:IQV opened at $271.01 on Tuesday. The business’s fifty day moving average price is $250.32 and its 200 day moving average price is $203.63. The firm has a market capitalization of $44.61 billion, a price-to-earnings ratio of 33.62, a PEG ratio of 2.31 and a beta of 1.18. The company has a current ratio of 0.71, a quick ratio of 0.71 and a debt-to-equity ratio of 2.18. IQVIA Holdings Inc. has a 1-year low of $154.50 and a 1-year high of $277.40.

IQVIA (NYSE:IQV) last released its earnings results on Tuesday, July 28th. The medical research company reported $3.15 earnings per share for the quarter, beating the consensus estimate of $3.03 by $0.12. The company had revenue of $4.37 billion for the quarter, compared to analysts’ expectations of $4.30 billion. IQVIA had a return on equity of 30.25% and a net margin of 8.10%.The business’s revenue for the quarter was up 8.7% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.81 EPS. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. On average, sell-side analysts forecast that IQVIA Holdings Inc. will post 11.56 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the stock. Apella Capital LLC increased its holdings in shares of IQVIA by 5.1% in the first quarter. Apella Capital LLC now owns 1,196 shares of the medical research company’s stock valued at $211,000 after purchasing an additional 58 shares during the period. Breakwater Capital Group boosted its position in IQVIA by 3.2% in the second quarter. Breakwater Capital Group now owns 2,073 shares of the medical research company’s stock valued at $401,000 after buying an additional 64 shares during the last quarter. First Growth Capital LLC increased its holdings in IQVIA by 3.2% in the 1st quarter. First Growth Capital LLC now owns 2,173 shares of the medical research company’s stock worth $375,000 after buying an additional 68 shares during the period. Root Financial Partners LLC lifted its stake in IQVIA by 31.0% during the 4th quarter. Root Financial Partners LLC now owns 296 shares of the medical research company’s stock valued at $67,000 after acquiring an additional 70 shares during the period. Finally, Chicago Partners Investment Group LLC boosted its holdings in shares of IQVIA by 1.5% in the 1st quarter. Chicago Partners Investment Group LLC now owns 4,635 shares of the medical research company’s stock valued at $812,000 after acquiring an additional 70 shares during the last quarter. 89.62% of the stock is owned by institutional investors.

Insider Activity at IQVIA

In other news, insider Bhavik Patel sold 1,855 shares of the company’s stock in a transaction dated Friday, July 31st. The stock was sold at an average price of $235.27, for a total value of $436,425.85. Following the sale, the insider owned 1,348 shares in the company, valued at $317,143.96. This represents a 57.91% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider W. Richard Staub sold 5,500 shares of IQVIA stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $232.68, for a total transaction of $1,279,740.00. Following the transaction, the insider directly owned 13,312 shares of the company’s stock, valued at approximately $3,097,436.16. This trade represents a 29.24% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 15,581 shares of company stock worth $3,796,021 in the last three months. Company insiders own 1.70% of the company’s stock.

Wall Street Analysts Forecast Growth

IQV has been the topic of several research analyst reports. BMO Capital Markets boosted their price target on shares of IQVIA from $210.00 to $270.00 and gave the company an “outperform” rating in a report on Wednesday, July 29th. TD Cowen raised their price target on IQVIA from $233.00 to $288.00 and gave the stock a “buy” rating in a research note on Wednesday, July 29th. Truist Financial reissued a “buy” rating and issued a $329.00 price target (up from $300.00) on shares of IQVIA in a research note on Monday. Mizuho lifted their target price on shares of IQVIA from $215.00 to $230.00 and gave the company an “outperform” rating in a research note on Monday, July 13th. Finally, William Blair raised shares of IQVIA to a “strong-buy” rating in a research report on Tuesday, July 28th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat.com, IQVIA presently has a consensus rating of “Moderate Buy” and a consensus price target of $253.25.

About Representative Hern

Kevin Hern (Republican Party) is a member of the U.S. House, representing Oklahoma’s 1st Congressional District. He assumed office on November 13, 2018. His current term ends on January 3, 2027.

Hern (Republican Party) is running for re-election to the U.S. House to represent Oklahoma’s 1st Congressional District. He declared candidacy for the 2026 election.

Kevin Hern went into business as a McDonald’s franchisee in 1999. He acquired 10 McDonald’s franchises by 2012. He served on the McDonald’s National Leadership Team for 13 years, including the tax policy team, the insurance corporation, and as chairman of the economics team. From 2011 to 2015, he was chairman of the finance committee of the Oklahoma Turnpike Authority.

IQVIA Company Profile

IQVIA Holdings Inc (NYSE: IQV) is a global provider of technology, analytics and contract research services for the life sciences industry. The company helps pharmaceutical, biotechnology and medical device organizations develop products, manage clinical trials, understand healthcare markets and improve commercial performance.

IQVIA’s offerings include clinical research and trial management, real-world data and evidence, healthcare analytics, technology platforms, consulting, and commercial services such as sales support and patient engagement.